The drug, designed by Pfizer, has many positives: It experienced an 89% reduction in the risk of hospitalization and death in unvaccinated individuals in the clinical trial that supported the EUA, a quantity that was high sufficient to prompt the Countrywide Institutes of Health (NIH) to prioritize it over other COVID-19 treatments. After the se